Videos | Antiplatelet and Anticoagulation Therapies
VIDEO: Use of Shorten DAPT and the Xience Stent in High-bleeding Risk Patients

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

Home October 19, 2020
Home
Videos | Heart Valve Technology
VIDEO: General vs Local Anesthesia for TAVR Addressed in SOLVE-TAVI Trial

Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local ...

Home October 19, 2020
Home
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab
No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

Home October 18, 2020
Home
The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the safety and effectiveness of the Medtronic  IN.PACT 0.014 drug-coated balloon (DCB) in critical limb ischemia (CLI) subjects with chronic total occlusion (CTO) in the infrapopliteal arteries. The data were presented in the Late-Breaking Clinical Trial Sessions at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual symposium of the Cardiovascular Research Foundation (CRF). #TCTconnect #TCT2020
News | Drug-Eluting Balloons
Drug-coated Balloon for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

Home October 18, 2020
Home
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020
News | Cath Lab
Combined FFR and OCT Imaging Can Improve Accuracy of High-Risk Lesion Identification in Patients With Diabetes

October 18, 2020 – Data from the COMBINE (OCT-FFR) study found that the use of FFR combined with OCT imaging can help ...

Home October 18, 2020
Home
Illustration showing how the near-infrared spectroscopy (NIRS) intravascular ultrasound (IVUS), of NIRS-IVUS, intracoronary imaging system can help identify angiographically non-obstructive lesions with high-risk characteristics for future adverse cardiac outcomes. The system can identify unstable, vulnerable plaques. #TCTconnect #TCT2020
News | Intravascular Imaging
NIRS-IVUS Imaging Can Help Identify High-Risk Plaques That Can Lead to Adverse Outcomes

October 18, 2020 – New data from the PROSPECT II study shows that near-infrared spectroscopy (NIRS) intravascular ...

Home October 18, 2020
Home
Videos | Cath Lab
VIDEO: Pre-emptive Treatment of Vulnerable Plaques With Bioresorbable Stents

Gregg Stone, M.D., presents the results of the PROSPECT ABSORB Trial in a press conference at the 2020 ranscatheter ...

Home October 17, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies
VIDEO: Bivalirudin vs. Heparin in Acute Myocardial Infarction Patients

Gregg Stone, M.D., presents the results of a pooled analysis of randomized trials of bivalirudin virus heparin in acute ...

Home October 17, 2020
Home
Videos | Heart Failure
VIDEO: Use of MitraClip as a Bridge to Heart Transplant

The late-breaking MitraBridge Study was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2020 meeting showed ...

Home October 16, 2020
Home
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0
Feature | Cath Lab
Shockwave Technology to Sonically Bust Calcified Coronary Lesions Shows Safety and Efficacy in U.S. Pivotal IDE Trial

October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ...

Home October 16, 2020
Home
Videos | Cath Lab
VIDEO: Demonstration of Intravascular Lithotripsy Breaking Up Calcium

This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heavily ...

Home October 16, 2020
Home
Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage closure (LAAC) CLAAS device performed in the U.S. and Prague were presented at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual meeting. Two two abstracts were presented by William Gray, M.D., from Lankenau Heart Institute, Wynnewood, Penn., and Vivek Reddy, M.D., from Mount Sinai Hospital in New York. #TCT2020 #TCTconnect
News | Left Atrial Appendage (LAA) Occluders
Conformal Medical CLAAS LAA Occluder Shows Promising Clinical Results at TCT 2020

October 16, 2020 — Positive clinical data from first-in-human studies of the Conformal Medical left atrial appendage ...

Home October 16, 2020
Home
The Abbott Vascular Xience Sierra drug eluting stent (DES). The XIENCE 28 and XIENCE 90 studies presented at TCT 2020 showed the stent can be used safely with only one month of dual antiplatelet therapy (DAPT). #TCT #TCTconnect #TCT2020
News | Stents Drug Eluting
Shorter DAPT With Xience Stent is Noninferior to Standard DAPT

October 16, 2020 – Results from the XIENCE 90/28 clinical trials have shown that a shorter course of dual-antiplatelet ...

Home October 16, 2020
Home
The Abiomed Impella was highlighted in several sessions at the 2020 TCT Connect conference. #TCT #TCT2020 #TCTconnect
News | Hemodynamic Support Devices
Restore EF Study Demonstrates Impella Supported High-Risk PCI Improves Left Ventricular Ejection Fraction

October 16, 2020 — The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more ...

Home October 16, 2020
Home
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect
News | Heart Valve Technology
Keystone Heart TAVR Embolic Protection Device Did Not Demonstrate Superiority 

October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart ...

Home October 15, 2020
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now